Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment

Journal of Cardiovascular Medicine

Volumn 9, Issue 1, 2008, Pages 51-55

  Rossillo, Antonio ^a,b   Bonso, Aldo ^a   Themistoclakis, Sakis ^a   Riccio, Giuseppe ^a   Madalosso, Michela ^a   Corrado, Andrea ^a   De Piccoli, Bruno ^a   Raviele, Antonio ^a  

^a Umberto I Hospital   (Italy)

^b Ospedale Umberto I   (Italy)

Author keywords

Ablation and atrial fibrillation; Oral anticoagulation therapy

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM CONTRACTILITY; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; INTRACARDIAC ECHOCARDIOGRAPHY GUIDED PULMONARY VEIN ANTRUM ISOLATION; MAJOR CLINICAL STUDY; MALE; PULMONARY VEIN OBSTRUCTION; RECURRENT DISEASE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CATHETER ABLATION; COMPARATIVE STUDY; DOSE RESPONSE; ECHOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PULMONARY VEIN; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PULMONARY VEINS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 40349113476     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32801462d4     Document Type: Article

References (26)

1. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of Chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28:973-977.
2. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1:526-529.
3. Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA 1999; 282:737-743.
4. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 28:175-179.
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457.
6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511.
7. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-539.
8. Stroke Prevention in Atrial Fibrillation II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet 1994; 343:687-691.
9. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-666.
10. Tsai CF, Tai CT, Hsieh MH, Lin WS, Yu WC, Ueng KC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100:1879-1886.
11. Marrouche NF, Martin DO, Wazni O, Gillinov AM, Klein A, Bhargava M, et al. Phased array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications. Circulation 2003; 107:2710-2716.
12. De Piccoli B, Rigo F, Ragazzo M, Zuin G, Martino A, Raviele A. Transthoracic and transesophageal echocardiographic indices predictive of sinus rhythm maintenance after cardioversion of atrial fibrillation. Echocardiography 2001; 18:545-552.
13. Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation. Stroke 2000; 32:2106-2111.
14. Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decision to prevent recurrence in stroke patients with atrial fibrillation? Stroke 2001; 32:2828-2832.
15. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in non-rheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998; 29:1827-1832.
16. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18:349-355.
17. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Non-rheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327:1406-1412.
18. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501.
19. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30:1223-1229.
20. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al., for the Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138:831-838.
21. Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, et al., for the National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005; 165:1185-1191.
22. Go AS, Hylek EM, Philipps KA, Borowsky LH, Henault LE, Chang Y, et al. Implication of stroke risk criteria on the anticoagulation decision in non-valvular atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2000; 102:11-13.
23. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation versus antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293:2634-2640.
24. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354:934-941.
25. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27:216-221.
26. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110:2287-2292.